Todd M Wilson

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation
    Y Bai
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Leukemia 27:278-85. 2013
  2. pmc Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 1881, USA
    Haematologica 96:459-63. 2011
  3. pmc mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells
    Daniel Smrz
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Blood 118:6803-13. 2011
  4. pmc KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells
    Eunice Ching Chan
    Mast Cell Biology Section, Laboratory of Allergic Diseases, Bethesda, MD, USA
    Exp Hematol 41:870-881.e2. 2013
  5. pmc IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
    J Allergy Clin Immunol 128:1086-92.e1-3. 2011
  6. pmc PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability
    Yasuko Furumoto
    Laboratory of Molecular Immunogenetics, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892, USA
    Blood 118:5466-75. 2011
  7. ncbi request reprint Treatment of systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11C205, 10 Center Drive, MSC 1881, Bethesda, MD 20892, USA
    Immunol Allergy Clin North Am 26:549-73. 2006

Collaborators

Detail Information

Publications7

  1. pmc Targeting the KIT activating switch control pocket: a novel mechanism to inhibit neoplastic mast cell proliferation and mast cell activation
    Y Bai
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Leukemia 27:278-85. 2013
    ..Overall, SP inhibitors represent an innovative mechanism of KIT inhibition whose dual suppression of KIT D816V neoplastic mast cell proliferation and SCF-enhanced mast cell activation may provide significant therapeutic benefits...
  2. pmc Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, 20892 1881, USA
    Haematologica 96:459-63. 2011
    ..Unlike other mature lineages, mast cell survival is dependent on KIT and the presence of these two activating mutations may have a greater impact on the expansion of this cell compartment and in resultant disease severity...
  3. pmc mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells
    Daniel Smrz
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892 1881, USA
    Blood 118:6803-13. 2011
    ....
  4. pmc KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells
    Eunice Ching Chan
    Mast Cell Biology Section, Laboratory of Allergic Diseases, Bethesda, MD, USA
    Exp Hematol 41:870-881.e2. 2013
    ..These data suggest that neoplastic mast cells favor a GNNK(-) variant predominance, which in turn enhances the activating potential of the KIT D816V mutation and thus could influence therapeutic sensitivity in systemic mastocytosis. ..
  5. pmc IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD
    J Allergy Clin Immunol 128:1086-92.e1-3. 2011
    ..Although IL-5, IL-3, and GM-CSF can modulate the expression of IL-5 receptor α (IL-5Rα) on eosinophils in vitro, little is known about soluble and surface IL-5Rα levels in vivo...
  6. pmc PTEN deficiency in mast cells causes a mastocytosis-like proliferative disease that heightens allergic responses and vascular permeability
    Yasuko Furumoto
    Laboratory of Molecular Immunogenetics, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892, USA
    Blood 118:5466-75. 2011
    ..Thus, Pten deletion in the mast cell compartment results in a mast cell proliferative phenotype in mice, demonstrating that dysregulation of PI3K signals is vital to the observed mast cell hyperplasia...
  7. ncbi request reprint Treatment of systemic mastocytosis
    Todd M Wilson
    Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Building 10, Room 11C205, 10 Center Drive, MSC 1881, Bethesda, MD 20892, USA
    Immunol Allergy Clin North Am 26:549-73. 2006
    ..This has directly translated into the development of novel targeted therapies. These therapies hold great promise to patients and health care providers that a "cure" for systemic mastocytosis may someday be obtainable...